You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

AREXVY LOGO

Product menu

Fist representing RSV moving across screen

Vaccination could help prevent* RSV-LRTD in your eligible patients1

Identify eligible patients for AREXVY and help play a part in RSV risk reduction.1

*Vaccination may not prevent RSV-LRTD in all recipients.1

Who is at risk of severe RSV-related outcomes?

Discover how RSV may be associated with an increased risk of hospitalisation in older adults, with or without comorbidities.2

Patient Risk Factors

  • Older female with mesh lung overlay representing COPD. Not an actual patient.
    COPD
    Lula - managing COPD, age 65
    For patients with COPD like Lula, RSV is associated with:
    • a 3.5 to 13.4-fold* increased risk of RSV-associated hospitalisation in adults aged ≥65 years compared to those without COPD2†
    • an accelerated decline in lung function3
    • airway inflammation that may impair viral clearance, leading to worsening respiratory symptoms4

    Exacerbations of COPD due to RSV can lead to hospitalisation.5

    *IRR 3.51(95% CI, 2.63–4.69); IRR 13.41(95% CI, 4.29–41.98.2
    Not an actual patient
  • Older female with mesh heart overlay representing heart failure. Not an actual patient.
    HEART FAILURE
    Bella - diagnosed with heart failure, age 70
    For patients with heart failure like Bella, RSV is associated with:
    • a 4.0 to 7.6-fold* increased risk of RSV-associated hospitalisation in adults aged ≥60 years compared to those without heart failure2†
    • an increased risk of heart failure exacerbations, arrhythmias and MI6,7
    • an increased risk of mortality within 1 year after RSV-related hospitalisation7‡

    RSV infection can increase the likelihood of mortality in patients with congestive heart failure exacerbation.7

    *IRR 3.99 (95% CI, 1.29–12.63); IRR 7.63 (95% CI, 2.43–23.93).2
    ‡Mortality within 1 year after admission and heart failure at baseline with current exacerbation.7
    Not an actual patient
  • Older male with mesh heart overlay representing coronary artery disease. Not an actual patient.
    CAD
    Dion - diagnosed with CAD, age 65
    For patients with CAD like Dion, RSV is associated with:
    • a 3.7 to 6.5-fold* increased risk of RSV-associated hospitalisation in adults aged ≥65 years compared to those without CAD2†

    *IRR 3.74 (95% CI, 1.19–11.78); IRR 6.46 (95% CI, 2.06–20.09).2
    Not an actual patient
  • Older male with mesh pancreas overlay representing diabetes. Not an actual patient.
    DIABETES
    Diego - diagnosed with diabetes, age 67
    For patients with diabetes like Dion, RSV is associated with
    • a 2.4 to 6.4-fold* increased risk of RSV-associated hospitalisation in adults aged ≥65 years compared to those without diabetes2†

    Diabetes is associated with an increased risk of severe outcomes from RSV infection.2

    *IRR 2.35 (95% CI, 1.82–3.04); IRR 6.44 (95% CI, 2.06–20.17).2
    Not an actual patient
  • Older male with mesh glasses overlay representing odler age. Not an actual patient.
    OLDER AGE
    Stefan - no pre-existing conditions, age 75
    For older patients like Stefan, RSV is associated with:
    • a 2.3 to 5.8-fold* increased risk of RSV-associated hospitalisation in adults aged ≥65 years compared to all adults aged ≥18 years2†

    Advancing age is associated with age-related decline in immunity.8 Patients hospitalised with RSV may require home care and face readmission within 3 months.9

    *IRR ranges are calculated using the highest IR per 100,000 for adults aged ≥65 years (255.56) divided by the lowest IR for all adults aged ≥18 years (44.22), and the lowest IR for adults aged ≥65 years (136.92) divided by the highest IR for all adults aged ≥18 years (58.86).2
    Not an actual patient

†US, single-state data. Based on data collected from 3 hospitals, New York–Presbyterian Hospital, Columbia University Irving Medical Center in New York City University of Rochester Medical Center, Strong Memorial Hospital in Rochester, New York, and Rochester Regional Health System, Rochester General Hospital in Rochester, New York, across 3 surveillance periods: 15 October 2017 to 30 April 2018, 15 October 2018 to 30 April 2019, and 15 October 2019 to 27 March 2020.2

Importance of Vaccination

HCPs play a pivotal role in helping patients get vaccinated11

Supporting patient conversations

Support confident decision-making in your eligible patients by addressing common vaccination queries

  • I’ve never heard of RSV. What is it?

    Emphasise the relevance of RSV by linking it to what patients may have already experienced.

    Explain how common and contagious it is, and how it spreads in relation to more familiar viruses, such as the cold or flu.6,7,12

  • If RSV is common and its symptoms are similar to a cold, is it really that bad if I get infected?

    Use personalised language to contextualise the risk of RSV-related complications to your patient's age, health status and lifestyle.

    Tailoring the risk in this way makes it more relevant and relatable to your eligible patients. This can support them in viewing vaccination as a proactive step to stay in control of their health and reduce the risk of serious illness.

  • I already have to get flu and COVID vaccines, I don’t have the time to schedule in another one.

    Frame the RSV vaccine as a preventative step to avoid serious illness, similar to the flu and COVID vaccines.13

    This positions it as a standard part of their ongoing health care. [Inform your at risk patients that AREXVY can be given alongside the flu vaccine or during any routine health visit1 so there is no need for a separate appointment.] Explain that a single dose also provides protection over 3 RSV seasons, meaning annual vaccination is not required.14

  • What are the side effects? How ill will I feel after having the vaccine?

    Reassure patients by clearly explaining what to expect after vaccination to help them feel informed and prepared.

    Most side effects are mild to moderate and transient.1 Let patients know that serious side effects are rare but explain what to look out for and what steps to take if they do occur.1,14

  • Are you sure the vaccine has been tested/studied enough?

    Inform eligible patients that AREXVY has been studied in more than 12,000 people across 17 countries and has published efficacy and safety data across 3 full RSV seasons.14

    If patients are interested in learning more, direct them to publicly available lay summaries of the research so they can explore it for themselves.

  • I think vaccines do more harm than good.

    Acknowledge the concern and help reframe it by helping patients understand the potential severity of RSV.7,15,16

    It could be helpful to remind eligible patients of the broader success of vaccines in preventing serious illness and protecting vulnerable groups.17

  • I’m not sure I trust pharmaceutical companies.

    Reassure patients by explaining that vaccines are thoroughly evaluated by independent regulatory bodies before they are approved, and that safety is continuously monitored in real-world settings.18

    Explain that your recommendation is based on evidence and guideline recommendations.

Abbreviations

CAD Coronary Artery Disease

CHF Congestive Heart Failure

CI Confidence Interval

COPD Chronic Obstructive Pulmonary Disease

HCP Healthcare Professional

IR Incidence Rate

IRR Incidence Rate Ratio

LRTD Lower Respiratory Tract Disease

MI Myocardial Infarction

RSV Respiratory Syncytial Virus

References

  1. Summary of Product Characteristics for AREXVY.
  2. Branche AR, Saiman L, Walsh EE, et al. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 20172020. Clin Infect Dis. 2022;74(6):1004–1011.
  3. Wilkinson TMA, Donaldson GC, Johnston SL, et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2006;173(8):871–876.
  4. Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev. 2019;28(151):180063.
  5. Osei-Yeboah R, Johannesen CK, Egeskov-Cavling AM, et al. Respiratory syncytial virus-associated hospitalization in adults with comorbidities in 2 European countries: a modeling study. J Infect Dis. 2024;229(Suppl 1):S70–S77
  6. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 Sep 10;366:l5021.
  7. Tseng HF, Sy LS, Ackerson B. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020;222(8):1298–1310.
  8. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
  9. Falsey AR, Walsh EE, House S, et al. Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults-A Global Study During the 2017–2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study). Open Forum Infect Dis. 2021;8(11):ofab491.
  10. Centers for Disease Control and Prevention. Weekly RSV Vaccination Dashboard. Updated May 2025. Accessed July 2025.
    Available from: https://www.cdc.gov/rsvvaxview/dashboard/index.html
  11. Centers for Disease Control and Prevention. Adult Immunization Standards. Updated August 2024. Accessed July 2025.
    Available from: https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.html
  12. Centers for Disease Control and Prevention. About RSV. Updated July 2025.
    Available from: https://www.cdc.gov/rsv/about/index.html
  13. Centers for Disease Control and Prevention. RSV Vaccine Guidance for Adults. Updated July 2025. Available from:
    Available from: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html.
  14. Ison MG, Papi A, Athan E, et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025;13(6):517–529.
  15. Hansen CL, Chaves SS, Demont C, et al. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. JAMA Netw Open. 2022;5(2):e220527.
  16. Penders Y, Brusselle G, Falsey AR, et al. Burden of respiratory syncytial virus disease in adults with asthma and chronic obstructive pulmonary disease: a systematic literature review. Curr Allergy Asthma Rep. 2025;25(1):14.
  17. Orenstein WA, Ahmed R. Simply put: Vaccination saves lives. PNAS. 2017;114(16):4031–4033.
  18. University of Oxford. How vaccines are tested, licensed and monitored. Updated August 2023.
    Available from: https://vaccineknowledge.ox.ac.uk/vaccine-development

 

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via the online form https://gsk.public.reportum.com/.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Arexvy is a registered trademark of the GlaxoSmithKline group of companies.

©2026 GSK group of companies. All rights reserved.

PM-IE-RSA-WCNT-260006 | September 2026